01 / PROFILE
Peptide Profiles
Each entry explains what the peptide is, why people search for it, the proposed mechanism, and where the evidence stops.
Hype, hope, or real? Side-by-side: what the internet is claiming, what the evidence backs up, and whether it’s worth your money.
Educational reference. Not medical advice.
Reality checks
Semax got HHS enforcement discretion in November 2026. Selank, its closest stack partner, didn't. The window to comment closes this Friday.
The dual GLP-1/glucagon agonist posted its strongest MASH data yet at AASLD 2026, and the liver findings may matter as much as the weight loss.
Cagrilintide is the long-acting amylin analog inside Novo Nordisk combination therapy — an FDA decision is expected this quarter, arriving after a complicated trial run that beat semaglutide and lost to tirzepatide.
The GH secretagogue behind the most-searched optimization stack got left off the enforcement discretion list that cleared TB-500, BPC-157, and four others last week.
One molecule, two identities, and a gray-market quality record that's running a 37% failure rate while the forums keep posting about it.
Last week HHS said pharmacies can compound TB-500. The endogenous protein TB-500 claims to fragment from just got its worst clinical review yet.
Search the index
How we cut through the noise
01 / PROFILE
Each entry explains what the peptide is, why people search for it, the proposed mechanism, and where the evidence stops.
02 / NEWS
Clickbait headlines with real receipts. Daily article on a trending peptide — what people are claiming, what the evidence actually shows, where the line is.
03 / SAFETY
Profiles include risks, unknowns, approval context, and clear boundaries around dosing, sourcing, and personal medical advice.
04 / CATEGORY
Compare fitness and recovery, GLP-1 and metabolic, longevity and skin, endogenous biology, and approved clinical peptides.
Should you take it?
PeptideFactCheck separates approved use, human signal, early research, preclinical biology, anecdotes, and unknowns so curiosity does not become fake certainty.
Why you can trust the verdicts
IUPHAR/BPS, PubChem, UniProt, RCSB PDB, PubMed, Europe PMC, and ClinicalTrials.gov are used for molecular and research context.
FDA Orange Book, DailyMed, openFDA, and FDA safety communications are used for U.S. regulatory and label context.
Vendor pages, forum posts, and clinic claims can explain public interest, but they are not treated as authoritative evidence.